PreludeDx™ DCISionRT® Predicts Radiation Benefit in Landmark Randomized SweDCIS Clinical Trial
/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced the...
Source: prnewswire.com